A recent announcement by Intellia Therapeutics and Kyverna Therapeutics showcased very promising research into a Car-T therapy focused on autoimmune disorders. The exclusive agreement between the two companies to both develop and then later commercialize a carefully-developed allogeneic CD19 chimeric Antigen Receptor (CAR) T-cell therapy which is aimed at treating …

Read More »